Farrell Simon

Launch success is shaped years before pivotal data—yet commercial insight is often introduced too late. This session explores how biotech leaders are embedding commercial strategy into early R&D decision-making to shape differentiation, access, evidence, and patient value from the outset. Panelists will share practical frameworks for stage-gated planning, early signal detection, target product profile (TPP) development, and lifecycle-aware evidence strategies that improve capital efficiency and launch readiness. Attendees will gain actionable approaches to aligning clinical, development, and commercial teams around shared, launch-driven objectives.

• Integrating commercial thinking at preclinical and Phase 1/2 milestones to inform TPP design, differentiation, and access strategy early.
• Using stage-gated, lifecycle-aware planning to connect development decisions directly to future launch success.
• Embedding payer, patient, and customer insights upstream to guide evidence generation and de-risk downstream commercialization.
• Strengthening cross-functional governance and scenario modeling to improve investment discipline and predictability.